Kalaris Therapeutics (KLRS) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 23.5% versus a loss of 62.1%. Kalaris Therapeutics is the larger company by market cap ($59.5 million vs $59.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | XLO |
|---|---|---|
| Share price | $2.50 | $9.01 |
| Market cap | $59.51M | $59.29M |
| 1-day change | -2.34% | 0.00% |
| YTD return | -70.38% | +0.56% |
| 1-year return | -62.06% | -23.48% |
| 5-year return | -99.51% | — |
| EPS (TTM) | $-1.97 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.88 | $12.59 |
| 52-week low | $2.35 | $6.47 |
| Distance from 52-week high | -78.96% | -28.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +648.40% | +121.98% |
| Average volume | 252.88K | 19.07K |
| Shares outstanding | 23.80M | 6.58M |
| Employees | 20 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed KLRS by 38.6 percentage points over the past year.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Healthcare · Biotechnology · 20 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Healthcare · Biotechnology · 76 employees
KLRS vs XLO FAQ
Which is bigger, Kalaris Therapeutics or Xilio Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $59.51M compared with $59.29M for Xilio Therapeutics (XLO).
Which stock has performed better over the past year, KLRS or XLO?
XLO returned -23.48% over the past 12 months, compared with -62.06% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.